Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Learn which dividend growth ETF is cheapest and how reducing costs can boost your net returns. Compare the options and pick the best value.
25,776 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Rivian is accelerating its growth story, but large-scale production and costly bets could temper enthusiasm. This in-...
Palantir posted 70% revenue growth in Q4 2025, led by US commercial gains and a robust free cash flow outlook. Trader...
If you missed the early AI stock surge, you still have a shot. This guide reveals two aggressive neocloud ideas and h...
Investors often wonder if AMD stock now is the right move. This guide analyzes the catalysts, risks, and practical st...
SpaceX is rumored to pursue a summer IPO valued at about $1.5 trillion, a move that would reshape public market norms...
Cardano has weathered wild crypto cycles before. This guide lays out credible scenarios for 2030, explains what could...
The OECD's June 2026 outlook warns of lasting damage to potential output from a protracted energy crisis, outlining t...
The BEA final read confirms economy grew 2.1% first quarter, signaling momentum. Here’s what drove growth and what ho...
Three clear visions for AMD in 2026, from AI-driven demand to capital returns. Learn what could move the stock and ho...
SentinelOne hit a $1 billion ARR milestone as revenue growth decelerated and operating margins improved, but investor...
As AI chips grab headlines, investors wonder if will cerebras soar after its IPO. While history offers clues, the pat...